Results 171 to 180 of about 9,465,904 (238)
Correction: Jamal et al. Preparation of 6-Mercaptopurine Loaded Liposomal Formulation for Enhanced Cytotoxic Response in Cancer Cells. Nanomaterials 2022, 12, 4029. [PDF]
Nanomaterials (Basel)Jamal A +7 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The genetic toxicology of 6-mercaptopurine
Mutation Research - Reviews in Genetic Toxicology, 1993Pasquale Mosesso +2 more
exaly +4 more sources
6-Mercaptopurine in Immunological Responsiveness
Nature, 1960Schwartz and Dameshek1,2 have reported the apparent production of immunological tolerance in rabbits by the administration of a purine analogue, 6-mercaptopurine. Rabbits receiving concomitantly human serum albumin and 6-mercaptopurine failed to develop an immune response to the protein antigen, and weeks later, when antigen alone was administered, the
J L, ROBINSON, C L, CHRISTIAN
openaire +2 more sources
Transplantation, 1973
SUMMARY A comparative study of the immunosuppressive activities of 6-mercaptopurine and its derivative azathioprine has been performed. It has been shown that in mice and rats, 6-mercaptopurine is markedly superior to azathioprine in reducing the number of spleen hemolytic plaque-forming cells when injected by parenteral routes, whereas azathioprine ...
F, Spreafico +5 more
openaire +2 more sources
SUMMARY A comparative study of the immunosuppressive activities of 6-mercaptopurine and its derivative azathioprine has been performed. It has been shown that in mice and rats, 6-mercaptopurine is markedly superior to azathioprine in reducing the number of spleen hemolytic plaque-forming cells when injected by parenteral routes, whereas azathioprine ...
F, Spreafico +5 more
openaire +2 more sources
Pediatrics International, 2001
Abstract Background : The poor absorption of orally administered 6‐mercaptopurine (6MP) causes a wide variation in its cytotoxic efficacy. An i.v. dosage form would eliminate this problem. Our objective was to compare the pharmacokinetics of 6MP administered orally with those of an i.v.
H, Mawatari +4 more
openaire +2 more sources
Abstract Background : The poor absorption of orally administered 6‐mercaptopurine (6MP) causes a wide variation in its cytotoxic efficacy. An i.v. dosage form would eliminate this problem. Our objective was to compare the pharmacokinetics of 6MP administered orally with those of an i.v.
H, Mawatari +4 more
openaire +2 more sources